Refractory Triple-Negative Breast Carcinoma
2 clinical trials · Condition
◉ Watch Refractory Triple-Negative Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
Track Refractory Triple-Negative Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.